Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase

Resistance to tyrosine kinase inhibitor (TKI) is a tough problem in the treatment of chronic myeloid leukemia in blastic phase (CML-BP), which was often associated with acquired mutations in the kinase domain and not eliminating the leukemic stem cells. The efficacy of TKI or combination with chemotherapy in CML-BP remains unsatisfactory. Chimeric antigen receptor T (CAR-T) cell immunotherapy may overcome TKI and chemotherapy resistance. However, lack of ideal targetable antigens is a major obstacle for treating patients with myeloid malignancies. CD38 is known to be expressed on most (acute myeloid leukemia) AML cells, and its lack of expression on hematopoietic stem cells renders it as a potential therapeutic target for myeloid CML-BP. We develop a CD38-directed CAR-T cell therapy for AML, and two patients with myeloid CML-BP were enrolled (NCT04351022). Two patients, harboring E255K and T315I mutation in the ABL kinase domain, respectively, were resistant to multiple TKIs (imatinib, dasatinib, nilotinib, and ponatinib) and intensive chemotherapy. The blasts in the bone marrow of two patients exhibited high expression of CD38. After tumor reduction chemotherapy and lymphodepletion chemotherapy, 1 × 107 CAR-T-38 cells per kilogram of body weight were administered. They achieved minimal residual disease–negative and BCR::ABL1-negative complete remission and experienced grade II cytokine release syndrome manifesting as fever. Our data highlighted that CAR-T-38 cell therapy may overcome TKI and chemotherapy resistance in patients with myeloid CML-BP.

[1]  A. E. Eşkazan,et al.  Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review , 2022, Expert review of hematology.

[2]  I. Haznedaroglu,et al.  Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. , 2021, European review for medical and pharmacological sciences.

[3]  M. Tiribelli,et al.  Asciminib as a new option in the treatment of chronic myeloid leukemia. , 2021, Future oncology.

[4]  Depei Wu,et al.  CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation , 2020, Journal of Hematology & Oncology.

[5]  Jiang F Zhong,et al.  Recent advances in CAR-T cell engineering , 2020, Journal of Hematology & Oncology.

[6]  Blastic Phase , 2020, Definitions.

[7]  S. Soverini,et al.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update , 2019, International journal of molecular sciences.

[8]  M. Konopleva,et al.  Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients , 2017, Cancer.

[9]  Genee Y. Lee,et al.  An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. , 2017, Blood.

[10]  Bie M. P. Verbist,et al.  Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. , 2016, Blood.

[11]  J. Szer,et al.  All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand , 2016, Bone Marrow Transplantation.

[12]  P. Parren,et al.  Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma , 2015, Haematologica.

[13]  Hao Jiang,et al.  Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis , 2014, Bone Marrow Transplantation.

[14]  Xiuli Wang,et al.  T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. , 2013, Blood.

[15]  Yan Zheng,et al.  Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. , 2013, Current opinion in immunology.

[16]  R. Hehlmann How I treat CML blast crisis. , 2012, Blood.

[17]  I. Bernstein,et al.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. , 2012, Blood.

[18]  R. Larson,et al.  Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase , 2012, Leukemia.

[19]  A. Hamilton,et al.  Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. , 2012, Blood.

[20]  H. Dombret,et al.  Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study , 2010, Cancer.

[21]  R. Zini,et al.  Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. , 2008, Blood.

[22]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[23]  H. Kantarjian,et al.  Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy , 2002, Cancer.

[24]  D. Marin,et al.  Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. , 2002, Blood.

[25]  M. Baccarani,et al.  Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia , 2016, Leukemia.

[26]  Teresa Foo,et al.  : SYSTEMATIC LITERATURE REVIEW , 2004 .

[27]  M. Konopleva,et al.  CD38 in hematopoietic malignancies. , 2000, Chemical immunology.

[28]  K. Johnson An Update. , 1984, Journal of food protection.